论文部分内容阅读
采用测定HBeAg阳性乙型肝炎血清HBV-DNA水平,判断分析,可耐对HBV的治疗作用。方法:56例HBeAg阳性的乙型肝炎接受可耐治疗,血清HBV-DNA浓度测定,应用AG-9600Ampisnsor荧光PCR定量系统,测定范围为10~(3.00)～9.50Copiesml。结果:56例HBeAg阳性的乙型肝炎患者,治疗结束时呈完全答应(CR)者48例,无答应者(NR)8例,对48例CR患者随访观察10个月,其中有11例血清ALT再度升高。血清HBV-DNA水平在治疗前,CR不伴有ALT再升高组,CR伴有ALT再升高组和NR组之间无差异,治疗结束时,CR不伴有ALT再升高组HBV-DNA为10~(3.44)±0.34Copiesml,明显低于CR伴有ALT再升高组。结论:HBeAg阳性的慢性肝炎病例,可耐治疗结束时检测DNA水平,对于判断疗效,有指导价值。HBV-DNA低于10~4Copiesml,往往能取得持久的疗效。
Using the determination of HBeAg-positive hepatitis B serum HBV-DNA levels, to determine the analysis, resistant to the treatment of HBV. Methods: Fifty-six patients with HBeAg-positive hepatitis B received resistance treatment and serum HBV-DNA concentration. The detection range was 10 ~ (3.00) ~ 9.50 Copies / ml using AG-9600Ampisnsor fluorescent quantitative PCR system. Results: Of the 56 patients with HBeAg-positive hepatitis B, there were 48 patients with complete response (CR) and 8 patients without response (NR) at the end of treatment. 48 patients with CR were followed up for 10 months, of which 11 patients ALT rises again. Serum HBV-DNA levels before treatment, CR was not associated with elevated ALT group, CR with ALT again elevated group and NR group no difference between the end of treatment, CR is not associated with ALT and then elevated HBV- DNA was 10 ~ (3.44) ± 0.34Copies ml, significantly lower than CR with ALT and then increased group. Conclusion: HBeAg-positive cases of chronic hepatitis, resistant to the end of treatment to detect DNA levels, for the judgment of efficacy, a guideline value. HBV-DNA less than 10 ~ 4Copies ml, often can achieve lasting efficacy.